Research programme: factor Xa inhibitors - Daiichi Sankyo

Drug Profile

Research programme: factor Xa inhibitors - Daiichi Sankyo

Alternative Names: DT-831j; R-142086

Latest Information Update: 15 Oct 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Amidines; Indoles; Pyridines; Small molecules; Sulfonamides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 31 Aug 2010 Preclinical development is ongoing in Japan (PO)
  • 23 Aug 2007 Clinical data presented at the 234th American Chemical Society National Meeting (234th-ACS-2007) added to the pharmacodynamics and pharmacokinetics sections
  • 14 Jun 2005 Preclinical trials in Thrombosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top